GlassScriptPhysician profile
Alexandra L Dodd
NPI 1902330277
$53,956.69
in general payments reported to CMS, 2019-2025
15 companies · $536 in 2025
The $536 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $567 · 2020: $116 · 2021: $225 · 2022: $1,918 · 2023: $13K · 2024: $37K · 2025: $536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Consulting Fee: $7,013 · Food and Beverage: $6,391 · Travel and Lodging: $2,812 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $34,835.00 |
| Consulting Fee | $7,012.50 |
| Food and Beverage | $6,390.94 |
| Travel and Lodging | $2,812.20 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $26,664.81 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $23,825.06 | 2019-2025 | Austedo Xr, Austedo, Uzedy |
| Janssen Pharmaceuticals, INC | $1,233.48 | 2019-2025 | Invega Sustenna |
| Alkermes, INC. | $771.37 | 2021-2025 | Lybalvi, Aristada, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $538.56 | 2019-2024 | Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $189.90 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $171.56 | 2022-2025 | Caplyta |
| Indivior INC. | $144.47 | 2022-2024 | Perseris |
| Sunovion Pharmaceuticals INC. | $125.39 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $119.27 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $91.30 | 2020-2025 | Fanapt |
| Boston Scientific Corporation | $24.16 | 2021 | |
| Shire North American Group INC | $22.38 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.88 | 2023 | |
| Lundbeck LLC | $17.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Dodd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.